CAR-T cancer Archives -

Johnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel)

Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA

https://pharmaphorum.com/news/chasing-bms-jj-files-bcma-car-t-for-multiple-myeloma-to-fda/

For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio

Gene therapy and market access: the pharmaphorum podcast

https://pharmaphorum.com/market-access-2/gene-therapy-market-access-podcast/

The UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies. Richard Staines

How the NHS got ahead of the curve with CAR-T

https://pharmaphorum.com/views-analysis-oncology/nhs-got-ahead-curve-car-t/

Pharma often criticises the NHS for failing to adopt the latest therapies, arguing that NICE’s technology appraisals can

Ahead of the curve

https://pharmaphorum.com/views-analysis-oncology/ahead-curve-car-t/

US cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T

Scotland’s TC BioPharm joins bluebird to develop next-gen CAR-T

https://pharmaphorum.com/news/scotlands-tc-biopharma-joins-bluebird-develop-next-gen-car-t/

CAR-T cancer